In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren

Diagnostic Microbiology and Infectious Disease

Volumn 42, Issue 1, 2002, Pages 59-64

  Karlowsky, James A ^a   Jones, Mark E ^b   Draghi, Deborah C ^a   Critchley, Ian A ^a   Thornsberry, Clyde ^a   Sahm, Daniel F ^a  

^a Focus Technologies Incorporated   (United States)

^b Focus Technologies   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFDITOREN; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

CEPHALOSPORINS; HUMANS; MICROBIAL SENSITIVITY TESTS; STREPTOCOCCUS PNEUMONIAE;

EID: 0036165868     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(01)00304-2     Document Type: Article

References (30)

1. Treatment of penicillin-resistant pneumococcal bacteremia in neutropenic patients with cancer
2. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States
3. Clonal relationships among high level penicillin resistant Streptococcus pneumoniae in the United States
4. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995
5. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program
6. Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to cefditoren, and provisional interpretative criteria
7. A double-blind, randomized study of cefditoren vs cefuroxime for AECB
8. Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984-1994
9. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species
10. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States
11. In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae
12. Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods
13. A multicenter comparison of cefditoren pivoxil and penicillin VK
14. Antimicrobial susceptibility: Data on outpatient respiratory isolates
15. Comparison of agar dilution, microdilution, E-test, and disk diffusion methods for testing activity of cefditoren against Streptococcus pneumoniae
16. Pneumococcal resistance to antibiotics
17. Phase I clinical trial of cefditoren pivoxil (ME 1207): Pharmacokinetics in healthy volunteers
18. Streptococcus pneumoniae
19. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain
20. Treating acute exacerbations of chronic bronchitis
21. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: A randomized study of amoxicillin-clavulanate and ceftriaxone
22. Identification of clinical risk factors for nosocomial pneumococcal bacteremia
23. Unique antibacterial properties of cefditoren: Pharmacokinetics of a new cephalosporin
24. Time-kill studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other β-lactams
25. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci
26. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987
27. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998
28. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in the 1996-1997 respiratory season